NEUP Neuphoria Therapeutics
Neuphoria Therapeutics earnings company data as of 4:48 AM ET 10/23
Scheduled
2 periods, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 13 Nov | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 5 Oct | EPS | -0.56 | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by NEUP's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
Lynx1 Capital Management LP 10% owner, +1 joint filerBuy$3.3M 639,110 shares at $5.14 +271% to stakeTraded Oct 21, 2025 Filed Oct 23, 2025
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 1.01,3.03,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| 10-K | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 1.01,5.01,7.01,9.01 | Filing Doc | |
| DEFA14A | CURRENT REPORT | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 10-Q | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 1.01,1.02,9.01 | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc | |
| 8-K | 3.01 | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| DEFA14A | DEFINITIVE ADDITIONAL MATERIALS | Filing Doc | |
| DEFA14A | DEFINITIVE ADDITIONAL MATERIALS | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc | |
| DEFA14A | DEFINITIVE ADDITIONAL MATERIALS | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc | |
| DEFA14A | DEFINITIVE ADDITIONAL MATERIALS | Filing Doc | |
| DEFA14A | DEFINITIVE ADDITIONAL MATERIALS | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.